metformin has been researched along with Cerebral Infarction in 4 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Cerebral Infarction: The formation of an area of NECROSIS in the CEREBRUM caused by an insufficiency of arterial or venous blood flow. Infarcts of the cerebrum are generally classified by hemisphere (i.e., left vs. right), lobe (e.g., frontal lobe infarction), arterial distribution (e.g., INFARCTION, ANTERIOR CEREBRAL ARTERY), and etiology (e.g., embolic infarction).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with metformin reduced mortality due to cardiovascular disease in obese patients." | 2.40 | [Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications]. ( Heine, RJ; Wolffenbuttel, BH, 1999) |
| "Then, stroke was induced by transient middle cerebral artery occlusion (tMCAO)." | 1.72 | Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat. ( Hong, JM; Joe, EH; Lee, JS; Lee, SJ; Yoon, BS, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, SJ | 1 |
| Yoon, BS | 1 |
| Hong, JM | 1 |
| Joe, EH | 1 |
| Lee, JS | 1 |
| Sood, A | 1 |
| Capuano, AW | 1 |
| Wilson, RS | 1 |
| Barnes, LL | 1 |
| Kapasi, A | 1 |
| Bennett, DA | 1 |
| Arvanitakis, Z | 1 |
| Wu, CS | 1 |
| Sung, SF | 1 |
| Tong, SH | 1 |
| Ong, CT | 1 |
| Wolffenbuttel, BH | 1 |
| Heine, RJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Dipeptidyl-4 Inhibitors in Reducing Stroke Severity, From the Health Insurance Review and Assessment Service Database[NCT05817097] | 22,119 participants (Anticipated) | Observational | 2023-08-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for metformin and Cerebral Infarction
| Article | Year |
|---|---|
[Glycemic regulation and management of essential hypertension in diabetics with type 2 diabetes mellitus; the 'United Kingdom prospective diabetes study' of diabetic complications].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 1999 |
3 other studies available for metformin and Cerebral Infarction
| Article | Year |
|---|---|
Effects of co-administration of metformin and evogliptin on cerebral infarct volume in the diabetic rat.
Topics: Animals; Brain Chemistry; Cerebral Infarction; Cerebrovascular Circulation; Diabetes Mellitus, Exper | 2022 |
Metformin, age-related cognitive decline, and brain pathology.
Topics: Alzheimer Disease; Brain; Cerebral Infarction; Cognition; Cognitive Dysfunction; Diabetes Mellitus; | 2024 |
Multiple cerebral infarctions related to famotidine-induced eosinophilia.
Topics: Acarbose; Adrenergic alpha-1 Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulc | 2012 |